Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 9/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 6/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17161867 | 0.98 | L3MBTL1 (0.49) | L3MBTL1JAK2JAK1TYK2NR3C2 | |
| SCHEMBL4587020 | 0.86 | TDP1 (0.50) | L3MBTL1NR3C2GSK3ALOXL2 | |
| SCHEMBL7671508 | 0.85 | L3MBTL1 (0.52) | L3MBTL1JAK2JAK1TYK2NR3C2 | |
| SCHEMBL91333 | 0.85 | RIOK2 (0.57) | L3MBTL1JAK2JAK1TYK2NR3C2 | |
| SCHEMBL501285 | 0.85 | L3MBTL1 (0.52) | L3MBTL1JAK2JAK1TYK2NR3C2 | |
| SCHEMBL9934078 | 0.85 | NR3C2 (0.51) | NR3C2LOXL2 | |
| SCHEMBL29507273 | 0.85 | L3MBTL1 (0.52) | L3MBTL1JAK2JAK1TYK2NR3C2 | |
| SCHEMBL31032910 | 0.84 | JAK2 (0.55) | JAK2JAK1TYK2NR3C2 | |
| SCHEMBL4305979 | 0.84 | JAK2 (0.55) | JAK2JAK1TYK2NR3C2 | |
| SCHEMBL20305452 | 0.84 | JAK2 (0.51) | L3MBTL1JAK2JAK1TYK2NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023009709-A1 | PYRAZOLO PIPERAZINES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2018119387-A1 | SMALL MOLECULE INHIBITORS OF COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) AND USES THEREOF | TESARO, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-9850225-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| WO-2015160641-A2 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | WO | disclosed |
| US-20150291549-A1 | Compounds Useful as Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-15 | — | — | US | disclosed |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | BAYER HEALTHCARE AG (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | BAYER HEALTHCARE AG (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | BAYER HEALTHCARE AG (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2006023707-A2 | 2-AMINOTHIOPHENECARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291549-A1 | Compounds Useful as Immunomodulators | CD74, HLA-DRB1, CD47 | L3MBTL1 3856/4885JAK2 730/4885JAK1 1052/4885 |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | ABCC3, HCCS, ABCC2 | L3MBTL1 2273/4885JAK2 896/4885JAK1 2385/4885 |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | MCL1, HDAC5, HDAC6 | L3MBTL1 3079/4885JAK2 315/4885JAK1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.